Showing results (51-60 of 131) with videos related to
Sort By:
Pageof 14
Breast Cancer Research and Treatment|June 30, 2011
Surgery of the primary tumor does not improve survival in stage IV breast cancerLaura Dominici, Julie Najita, Melissa Hughes, et al.Medical Care|November 15, 2017
Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon CancerAnil Vachani, Yu-Ning Wong, Jennifer Israelite, et al.Urology Case Reports|September 13, 2016
Biology is Destiny: A Case of Adrenocortical Carcinoma Diagnosed and Resected at Inception in a Patient Under Close Surveillance for Lung CancerBenjamin Miron, Benjamin T Ristau, Jeffrey J Tomaszewski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinomaYu-Ning Wong, Samuel Litwin, David Vaughn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Preoperative delays in the US Medicare population with breast cancerRichard J Bleicher, Karen Ruth, Elin R Sigurdson, et al.Clinical Genitourinary Cancer|December 3, 2014
A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSiteMatthew Zibelman, Peter Barth, Elizabeth Handorf, et al.Practical Radiation Oncology|October 26, 2011
PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix DefinitionTracy L Klayton, Karen Ruth, Mark K Buyyounouski, et al.Medical Care|July 23, 2013
Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative settingYu-Ning Wong, Brian L Egleston, Kush Sachdeva, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 11, 2018
Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in SituMichael J Hassett, Wei Jiang, Melissa E Hughes, et al.Investigational New Drugs|June 21, 2015
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumorsMatthew Zibelman, Yu-Ning Wong, Karthik Devarajan, et al.Pageof 14